National HIV CurriculumLogo
Share

Bictegravir-Lenacapavir (Bixlenvo)

All References

Filter by Category
  • All References
  • Clinical Studies
    • Treatment-Naive
    • Treatment-Experienced
    • Switch/Simplification
    • Dual Therapy
    • Monotherapy
    • PREP
    • PEP
    • Acute HIV
  • Resistance/Virological Failure
  • Pharmacology
    • General Pharmacology
    • Adverse Effects
    • Drug Interactions
  • Pregnancy/Women
  • Pediatrics
  • Review
  • Jayaweera DT, AlBukhari M, Pabon F, et al. Evaluating the combination of bictegravir and lenacapavir as a single tablet option for HIV. Expert Opin Pharmacother. 2026;27:1231-41.
    [PubMed Abstract]
  • Meissner EG, Ramgopal M, Ruane PJ, et al. Safety and efficacy of switching to bictegravir-lenacapavir versus continuing bictegravir-emtricitabine-tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet HIV. 2026;13:e538-e547.
    [PubMed Abstract]
  • Mounzer K, Slim J, Ramgopal M, et al. Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at Baseline. Open Forum Infect Dis. 2025;12:ofaf615.
    [PubMed Abstract]
  • Mounzer K, Slim J, Ramgopal M, et al. Efficacy and Safety of Switching to Daily Bictegravir Plus Lenacapavir From a Complex HIV Treatment Regimen: A Randomized, Open-Label, Multicenter Phase 2 Study (ARTISTRY-1). Clin Infect Dis. 2025;80:881-8.
    [PubMed Abstract]
  • Orkin C, Ruane PJ, Hedgcock M, et al. Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial. Lancet. 2026;407:1249-58.
    [PubMed Abstract]
  • Pennetzdorfer N, Naik V, Montezuma-Rusca JM, Sklar P, Callebaut C, Margot NA. Baseline and week 48 resistance analysis in participants receiving bictegravir + lenacapavir in the phase 2 ARTISTRY-1 study. AIDS. 2026;40:1140-45.
    [PubMed Abstract]
  • Pennetzdorfer N, Naik V, Montezuma-Rusca JM, Sklar P, Callebaut C, Margot NA. Week 96 resistance analysis in participants receiving bictegravir/lenacapavir in the phase 2 ARTISTRY-1 study. Antivir Ther. 2026:13596535261481194.
    [PubMed Abstract]

Share by e-mail

The Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS) provided financial support for this website. The award provided 100% of total costs and totaled $1,172,990. The contents are those of the author. They may not reflect the policies of HRSA, HHS, or the U.S. Government.

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.